Date: 2017-06-26
Type of information: Nomination
Compound: board of directors
Company: Nabriva Therapeutics (Ireland)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On June 26, 2017, Nabriva Therapeutics announced the appointment of Carrie Bourdow, Senior Vice President and Chief Commercial Officer of Trevena, to its Board of Directors. With the completion of the company’s redomicile from Austria to Ireland, Colin Broom, Chief Executive Officer of Nabriva will also join the Board of Directors.
- Ms. Bourdow has served as Senior Vice President and Chief Commercial Officer of Trevena since 2015. Previously, she was Vice President of Marketing, Reimbursement and Operations at Cubist Pharmaceuticals. Prior to joining Cubist, she spent more than 20 years at Merck & Co, where she held positions across several therapeutic areas including anti-infectives, acute heart failure and pain. Ms. Bourdow holds a B.A. degree from Hendrix College and earned her M.B.A. from Southern Illinois University.
- The appointees will serve alongside existing Board members, including Chairman Daniel Burgess of SV Life Sciences, Axel Bolte of HBM Partners; Mark Corrigan, M.D., former President and Chief Executive Officer of Zalicus; Chau Quang Khuong of OrbiMed Advisors ; George Talbot of Talbot Advisors; Charles Rowland, former CEO of Aurinia Pharmaceuticals; and Stephen Webster, CFO of Spark Therapeutics.
Financial terms:
Latest news:
Is general: Yes
